Portal vein thrombosis screening in select contexts
Adjunct only in ED AMI workup
Disposition
Level of care decisions
Admission and monitoring needs
ICU indications
Shock
Vasopressor requirement
Persistent metabolic acidosis
Rising lactate mmol/L
Step-down indications
Stable after intervention with ongoing risk of reperfusion injury
Ward-level rare scenarios
Confirmed isolated mesenteric venous thrombosis with stability and no peritonitis
Transfer considerations
Centre capability needs
Endovascular revascularization availability
Vascular surgery availability
ICU bed availability
Time-critical transfer triggers
Arterial occlusion on CTA without local revascularization option
Discharge criteria
Discharge not typical
AMI generally requires admission
Outpatient management not appropriate for suspected AMI
Treatment
Resuscitation and supportive care
Physiologic stabilization
IV crystalloids
Balanced crystalloid initial bolus 10-20 mL/kg
Reassessment after each bolus
Vasopressors for shock
Norepinephrine infusion initiate for MAP < 65 mmHg after fluids
Titrate every 2-5 minutes to MAP target
Peripheral administration as bridge with close monitoring
Vasopressin adjunct if escalating norepinephrine
Fixed-dose strategy per ICU protocol
Oxygenation and ventilation
Supplemental oxygen for hypoxaemia
Intubation if refractory shock or inability to protect airway
Nasogastric decompression considerations
Ileus or vomiting
Aspiration risk reduction
Temperature management
Normothermia target
Active warming if hypothermia
Anticoagulation
Unfractionated heparin
Indications
Suspected arterial embolism or thrombosis without contraindication
Mesenteric venous thrombosis
Dosing and monitoring
Bolus 80 units/kg IV
Omit bolus if high bleeding risk
Infusion 18 units/kg/hour IV
Titrate to aPTT target per institutional protocol
Contraindications
Active major bleeding
Suspected intracranial haemorrhage
Severe thrombocytopenia
Antibiotics
Broad-spectrum coverage
Indications
Suspected transmural ischaemia
Peritonitis
Sepsis physiology
Preoperative coverage
Regimens
Piperacillin-tazobactam 4.5 g IV q6-8h
Renal adjustment as needed
Ceftriaxone 2 g IV daily
Metronidazole 500 mg IV q8h
Meropenem 1 g IV q8h for high ESBL risk
Renal adjustment as needed
Revascularization and definitive management
Arterial embolism strategy
Endovascular options
Catheter-directed thrombectomy
Best for proximal embolus in stable patient
Catheter-directed thrombolysis
Bleeding risk assessment required
Operative options
Open embolectomy
Peritonitis
Failed endovascular therapy
Bowel assessment and resection
Nonviable bowel
Arterial thrombosis strategy
Endovascular options
Angioplasty and stenting
Ostial SMA disease
Thrombectomy adjunct
Acute-on-chronic occlusion
Operative options
Mesenteric bypass
Extensive occlusive disease
Hybrid revascularization
Laparotomy with retrograde SMA stenting
Non-occlusive mesenteric ischaemia strategy
Perfusion optimization
Reduce vasopressor dose if feasible
Correct hypovolaemia
Treat underlying shock driver
Intra-arterial vasodilators in specialist care
Papaverine infusion via catheter
Specialist-directed dosing and monitoring
Mesenteric venous thrombosis strategy
Anticoagulation as main therapy
UFH transition to longer-term anticoagulation when stable
Catheter-directed thrombolysis considerations
Extensive thrombosis with deterioration despite anticoagulation
Specialist-directed bleeding risk management
Surgery triggers
Peritonitis
Suspected infarction
Operative management and post-op strategies
Laparotomy principles
Bowel viability assessment
Colour and peristalsis
Mesenteric arterial pulsation
Adjunct perfusion assessment tools when available
Resection strategy
Clearly necrotic bowel only in first pass when borderline segments
Bowel preservation when viable uncertainty
Second-look laparotomy
Planned 24-48 hours for borderline bowel
Post-revascularization care
Reperfusion injury monitoring
Rising lactate mmol/L
Hyperkalaemia
Worsening acidosis
Nutrition strategy
Early enteral feeding when feasible
Parenteral nutrition if short bowel risk
Special Populations
Pregnancy
Pregnancy considerations
Differential expansion
Ovarian torsion
Placental abruption
HELLP syndrome
Imaging considerations
CTA use when maternal life at risk
Shielding and dose optimization
Anticoagulation considerations
UFH preferred for procedural flexibility
LMWH transition planning with obstetrics
Multidisciplinary coordination
Obstetrics consult for viable gestation
Foetal monitoring when appropriate
Geriatric
Older adult considerations
Atypical presentations
Blunted pain report
Delirium predominant
Higher pretest probability
Atrial fibrillation prevalence
Atherosclerosis burden
Medication considerations
Renal dosing adjustments
Higher bleeding risk with thrombolysis
Goals of care integration
Early discussion in severe infarction or frailty
Pediatrics
Paediatric considerations
Rarity of classic AMI
Alternate causes more common
Important mimics
Midgut volvulus
Intussusception
Necrotizing enterocolitis in neonates
Thrombotic risk contexts
Congenital heart disease
Central venous lines
Inherited thrombophilia
Weight-based anticoagulation
Specialist-guided UFH dosing and monitoring
Background
Epidemiology
Epidemiologic features
High mortality condition
Outcome strongly time-dependent
Aetiology distribution concepts
Arterial embolism common in atrial fibrillation
Arterial thrombosis associated with atherosclerosis
NOMI associated with low-flow states
Mesenteric venous thrombosis associated with hypercoagulability
Risk enrichment settings
ICU vasopressor exposure
Post-cardiac surgery
Pathophysiology
Core mechanisms
Supply-demand mismatch
Reduced mesenteric blood flow
Increased oxygen demand
Ischaemia progression
Mucosal hypoxia to barrier failure
Bacterial translocation
Transmural infarction
Reperfusion injury
Reactive oxygen species surge
Capillary leak and oedema
Systemic inflammatory response
Aetiology-specific mechanisms
Embolus lodging in SMA
Thrombus on chronic stenosis
Splanchnic vasoconstriction in NOMI
Venous outflow obstruction with oedema and reduced inflow
Therapeutic Considerations
Time-critical principles
Early CTA improves diagnosis and pathway to revascularization
ACEP Level C recommendation based on consensus for suspected AMI imaging urgency
Early revascularization improves bowel salvage likelihood
Class I recommendation based on expert consensus
Anticoagulation reduces thrombus propagation
Class I recommendation based on expert consensus
Antibiotics reduce infectious complications in transmural injury risk
Class I recommendation based on expert consensus
Damage control strategy
Second-look laparotomy for borderline bowel
Physiologic optimization before definitive reconstruction
Patient Discharge Instructions
copy discharge instructions
Discharge instructions after hospitalization or intervention
Follow-up plan
Surgery follow-up timeline per discharge summary
Vascular follow-up for revascularization surveillance
Anticoagulation clinic follow-up if prescribed
Medication safety
Anticoagulant adherence
Bleeding precautions
Diet and hydration
Gradual diet advancement per surgical guidance
Hydration goals if high-output ostomy
Return to ED now
Severe or worsening abdominal pain
Blood in stool or black stool
Persistent vomiting
Fever
Fainting or new confusion
Chest pain or shortness of breath
Uncontrolled bleeding if on anticoagulant
References
Clinical guidelines and key sources
Guideline and consensus sources
World Society of Emergency Surgery guidance on acute mesenteric ischaemia
Early CTA as first-line imaging in suspected AMI
Early revascularization and bowel assessment pathways
Society for Vascular Surgery guidance on mesenteric ischaemia
Endovascular-first considerations in suitable anatomy
Critical care sepsis guidelines
Norepinephrine first-line vasopressor for septic shock
Early broad-spectrum antibiotics for suspected intra-abdominal sepsis
Evidence-based reviews and landmark concepts
Diagnostic performance summaries for CTA in AMI
High sensitivity and specificity for arterial occlusion in modern multidetector CTA
Mesenteric venous thrombosis management reviews
Anticoagulation as cornerstone therapy
Damage control and second-look laparotomy literature
Planned reassessment improves bowel preservation in borderline viability
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.